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Transmission of Kaposi sarcoma–associated herpesvirus (KSHV) is mainly through salivary exchange and can occur in 
childhood in endemic regions1; KSHV prevalence increases with 
age.2 The impact of age of infection with KSHV on the pathogen-
esis and control of KSHV has not been investigated.
Early infection with Epstein-Barr virus (EBV), another 
gammaherpesvirus closely related to KSHV, is associated with 
higher subsequent viral load.3 High viral capsid antigen antibody 
titers and EBV viral load have been associated with risk of Burkitt 
lymphoma,4 the most common childhood malignancy in equatorial 
Africa, linked to both EBV and malaria.5
High antibody titers to KSHV are an important predictors 
of risk of Kaposi’s sarcoma (KS) disease6; they are also a marker 
of KSHV reactivation.7 This study was designed to determine the 
association between the age at which children from Uganda become 
KSHV seropositive (KSHV seroconversion age) and subsequent 
KSHV-specific immunoglobulin G (IgG) antibody values.
METHODS
Study Population
Samples collected from children enrolled in the Entebbe 
Mother and Baby Study were tested for KSHV IgG antibody 
responses retrospectively. Entebbe Mother and Baby Study was 
initiated as a randomized controlled trial, designed to investigate 
the impact of helminth treatment during pregnancy on childhood 
responses to vaccines and infectious diseases. The trial protocol and 
results have been described elsewhere.8 A total of 2507 pregnant 
women from Entebbe, Uganda, a semiurban area, were recruited 
and their children have been followed from birth. Blood and other 
samples have been collected annually and stored.
Ethical Approval
This study was approved by the Uganda Virus Research 
Institute—Research and Ethics Committee, the Uganda National 
Council for Science and Technology and the London School of 
Hygiene & Tropical Medicine. Informed consent was obtained 
from study participants’ parents or guardians.
KSHV Serologic Testing
Plasma samples collected at 6 years of age (annual 6) were 
tested for KSHV IgG antibodies to identify KSHV seropositive 
children. KSHV seropositivity was defined by seropositivity to 
either ORF73 or K8.1 antigen. Any seropositive child was then 
tested at age 5, and so on retrospectively, until a seronegative speci-
men was identified. To determine if the effect of age at infection on 
subsequent antibody values is sustained for a longer time period, 
we then tested the available plasma samples at age 9 from the 
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children who were seropositive at age 6 for IgG antibody responses 
to KSHV. The estimated age of KSHV seroconversion was defined 
as the midpoint between the last seronegative and the first seroposi-
tive specimen. Because of missing specimens, these samples were 
not always from consecutive years.
An in-house multiplexed bead assay was used to measure 
KSHV-specific IgG antibody responses as previously described.9 
This assay has a wider dynamic range than an enzyme-linked 
immunosorbent assay which is an important advantage when com-
paring antibody values. ORF73 and K8.1 recombinant proteins 
were coupled to fluorescent magnetic beads (Biorad, Hercules, 
CA) according to the manufacturer’s protocol. Coupled beads were 
mixed with plasma samples at a sample dilution of 1/200 and a 
bead concentration of 2000 beads per well in assay/wash buffer (1% 
bovine serum albumin in 1 × phosphate buffered saline), to make 
a total volume of 100 µ per well. The mixture was incubated for an 
hour under gentle agitation and washed with wash buffer thereafter. 
Detection antibody of 100 µ of 0.5µL/mL [goat F(ab′)2 antihuman 
IgG R-phycoerythrin (R-PE) conjugate] was added and incubated 
for 30 minutes under gentle agitation. After washing, 100 µ of assay 
TABLE 1. Association Between Age of KSHV Seroconversion, Sex, Age and KSHV Antibody Levels Among Children 
From Uganda
AI: Antibody Levels at Age 6 yr From 158 Children
 
K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.81 (0.72–0.90) <0.0001 0.81 (0.73–0.91) <0.0001 0.73 (0.64–0.83) <0.0001 0.73 (0.64–0.83) <0.0001
AII: Antibody Levels at Age 6 yr From 100 Children With All Consecutive Samples
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.78 (0.69–0.89) <0.0001 0.80 (0.70–0.37) 0.001 0.69 (0.59–0.81) <0.0001 0.68 (0.58–0.80) <0.0001
BI: Antibody Levels at Age 9 yr From 158 Children
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.67 (0.57–0.79) <0.0001 0.67 (0.57–0.79) <0.0001 0.75 (0.66–0.85) <0.0001 0.75 (0.66–0.85) <0.0001
BII: Antibody Levels at Age 9 yr From 100 Children With All Consecutive Samples
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.96 (0.78–1.18) 0.691 0.95 (0.77–1.17) 0.620 1.03 (0.88–1.19) 0.740 1.03 (0.88–1.20) 0.737
CI: Antibody Levels at Ages 1, 2, 3, 4, 5, 6 and 9 yr From 158 Children
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted† GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted GMR† 
(95% CI) P
Seroconversion age 0.72 (0.66–0.78) <0.0001 0.60 (0.55–0.65) <0.0001 0.71 (0.65–0.77) <0.0001 0.59 (0.53–0.64) <0.0001
Age 0.93 (0.85–0.99) 0.018 1.70 (1.57–1.85) <0.0001 0.82 (0.76–0.88) <0.0001 1.65 (1.53–1.77) <0.0001
CII: Antibody Levels at Ages 1, 2, 3, 4, 5, 6 and 9 yr From 100 Children With All Consecutive Samples
 K8.1 ORF73
Crude GMR  
(95% CI)
P Adjusted† GMR 
(95% CI)
P Crude GMR  
(95% CI)
P Adjusted GMR† 
(95% CI)
P
Seroconversion age 0.80 (0.73–0.87) <0.0001 0.73 (0.67–0.80) <0.0001 0.78 (0.72–0.85) <0.0001 0.68 (0.62–0.75) <0.0001
Age 1.09 (1.02–1.17) 0.008 1.20 (1.12–1.28) <0.0001 1.22 (1.15–1.03) <0.0001 1.29 (1.22–1.37) <0.0001
*Adjusted for sex and seroconversion age.
†Adjusted for age, sex and seroconversion age.
AI and AII show the association between age of KSHV seroconversion, sex and KSHV antibody levels at age 6. BI and BII show the association between age of KSHV seroconver-
sion, sex and KSHV antibody levels at age 9. CI and CII show the association between age of KSHV seroconversion, sex, age and KSHV antibody levels among children at ages 1, 
2, 3, 4, 5, 6 and 9 combined from Uganda. AI and CII show results from 100 children with all 6 consecutive samples plus 58 children missing 1–4 samples. AII and CII show results 
from 100 children with all 6 consecutive samples. BI shows results from 130 children with samples available at age 9. BII shows results from 79 children with available samples at 
age 9, and have all previous consecutive samples. GMR and 95% CI obtained by calculating the log10 exponent of the regression coefficient and the 95% CI, respectively. Regression 
coefficient, 95% CI and P value were obtained using linear regression after log10 transformation of K8.1- and ORF73-specific total IgG MFI. MFI was obtained using the bead assay. 
K8.1 and ORF73 IgG antibody responses were analyzed using separate linear regression models. Seroconversion age is the age at which the children became KSHV seropositive. Age 
is the number of years the children had lived by the time of sample collection.
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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buffer was added per well, agitated for 2 minutes and the plate read 
using a Bioplex200 machine (Luminexcorp, Austin, TX) to obtain 
the median fluorescence intensities (MFIs). Each plate contained 3 
negative and 3 positive control wells plus 2 blank wells. The cutoff 
MFI values for OFR73 and K8.1 were 968 and 741, respectively, 
plus the mean values of the negative control per plate.
Statistical Analysis
Data analysis was performed using Stata-13 software 
(STATA 13.0; Statacorp, College Station, TX). Antibody values 
(measured as MFIs) were log
10
 transformed. Linear regression was 
used to examine the relationship between KSHV IgG antibody 
responses at 6 and 9 years of age and seroconversion age while 
adjusting for sex. To investigate the association between serocon-
version age and antibody values (KSHV IgG antibodies) at all time-
points/ages (1, 2, 3, 4, 5, 6 and 9), we used mixed models with ran-
dom effects. Random-effects modeling provided associations that 
were independent of the duration of infection and accounted for 
correlation of results from the same child at different time points. 
Geometric mean ratios (GMRs) and their 95% confidence intervals 
(CIs) were obtained by calculating the log
10
 exponent of the regres-
sion coefficients and their 95% CI, respectively. Antibodies to K8.1 
and ORF73 were analyzed using separate regression models.
RESULTS
Age at KSHV Seroconversion
The number of children who were KSHV seropositive at 6 
years of age was 176/535 (33%), 128/535 (24%) were seropositive 
to K8.1 and 165/535 (31%) were seropositive to ORF73 proteins. 
The number of children with all 6 consecutive samples was 100/176. 
Therefore, 76/176 children had at least 1 missing sample, 39, 11, 5, 
3 and 18 had 1, 2, 3, 4 and 5 missing samples, respectively. The 18 
children with 5 consecutive missing samples were excluded from the 
analysis, leaving a total of 158 children for analysis. Results from 
100 participants with all 6 consecutive samples (Table 1, AII and 
CII) were comparable to those from 158 participants (Table 1, AI 
and CI) at 6 years of age and at all ages combined. At 9 years of 
age, the available samples from the 100 participants were 79 which 
might have reduced the power of the study to detect statistically sig-
nificant differences (Table 1, BII). Among the 158 KSHV seroposi-
tive 6-year-old children analyzed, 43, 50, 23, 14, 18 and 10 children 
were estimated to have seroconverted by ages 6, 5, 4, 3, 2 and 1, 
respectively. The proportions of seroconverters who were boys at the 
different seroconversion age bands were 22/43 (51%), 26/50 (52%), 
14/23 (61%), 8/14 (57%), 10/18 (56%) and 8/10 (80%) at 6, 5, 4, 
3, 2 and 1, respectively. Antibody values increased with age. For 
every annual increase in age, we observed a 71% (P < 0.0001) and 
65% (P < 0.0001) increase in K8.1 and ORF73 IgG antibody values, 
respectively (Table 1, CI). On the other hand median antibody values 
generally decreased with increasing age at primary infection (Fig., 
Supplemental Digital Content 1, http://links.lww.com/INF/C950).
We investigated the association between age at KSHV 
seroconversion and antibody values to K8.1 and ORF73 antigens 
at 6 and 9 years of age using sex-adjusted linear regression mod-
eling. At 6 years of age, antibody values decreased with increas-
ing seroconversion age. For every year of delay in seroconver-
sion age, we observed a 19% decrease in K8.1 antibody values, 
with an adjusted GMR (aGMR) of 0.81, 95% CI (0.73–0.91), P 
= 0.001 (Table 1, AI). In addition, for every year of delay in sero-
conversion age, we observed a 27% decrease in ORF73 antibody 
values, with an aGMR of 0.73, 95% CI (0.64–0.83), P < 0.0001 
(Table 1, AI).
At 9 years of age, both K8.1 and ORF73 antibody values 
decreased with increasing seroconversion age. For every year of 
delay in seroconversion age, we observed a 33% decrease in K8.1 
antibody values, with an aGMR of 0.67, 95% CI (0.57–0.79), P 
> 0.0001 (Table 1, BI). Similarly, for every year of delay in sero-
conversion age, we observed a 25% decrease in ORF73 antibody 
values, with an aGMR of 0.75, 95% CI (0.66–0.85), P < 0.0001 
(Table 1, BI).
To determine the effect of age of infection on antibody titers 
which is independent of duration of infection, we then investigated 
the association between seroconversion age and antibody values at 
all ages/timepoints (1, 2, 3, 4, 5, 6 and 9) to K8.1 and ORF73 using 
random-effects models adjusting for sex and age. Generally, anti-
body values to both K8.1 and ORF73 decreased with increasing 
seroconversion age. For every year of delay in seroconversion, we 
detected a 40% decrease in K8.1 antibody values, aGMR 0.60, 95% 
CI (0.55–0.65), P < 0.0001 (Table 1, CI). Similarly, for every year 
of delay in seroconversion, we observed a 41% reduction in ORF73 
IgG antibody values, aGMR 0.59, 95% CI (0.53–0.64), P < 0.0001 
(Table 1, CI).
DISCUSSION
In KSHV endemic areas, infection can occur early in life, 
but the importance of age of infection to subsequent transmis-
sion and disease risk has not been investigated before. Antibody 
responses to KSHV, and in particular, values of antibodies, have 
been associated with KS development, KSHV reactivation and 
KSHV transmission.6,7. In this study, we have observed very early 
seroconversions and detected a strong association between age of 
KSHV seroconversion and subsequent antibody values to both K8.1 
and ORF73. The earlier these children seroconverted, the higher 
their subsequent antibody values to both K8.1 and ORF73 proteins. 
To our knowledge, this is the first study to look at the effect of age 
of infection with KSHV on subsequent antibody responses. Anti-
body responses are a proxy measure of KSHV reactivation.6 K8.1 
is a glycoprotein expressed during the lytic phase of the virus life 
cycle and ORF73 encodes the latently associated nuclear protein, 
a structural protein expressed during the latent stage of the virus 
life cycle. Measurement of other parameters related to disease and 
transmission risk such as viral load in saliva and in blood in relation 
to KSHV age of infection would be of great interest.
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with cardiovascular risk factors in children.
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Inflammation is central to the development of atherosclerosis, and pathogenic lesions in arteries are reported from early childhood 
onward.1 Children with acute and chronic inflammatory diseases, 
including Kawasaki disease, inflammatory bowel disease, psoriasis 
and juvenile arthritis may have persistent adverse changes in their vas-
cular structure and function, although the implications for later cardi-
ovascular disease risk are largely unknown.2–4 Toxic shock syndrome 
(TSS) is a rare, acute, life-threatening toxin-mediated illness causing 
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
DOI: 10.1097/INF.0000000000001821
2017
fulminant vascular inflammation and dysfunction, often resulting in 
multiorgan failure. It is unknown whether children with TSS have 
changes in either the macro- or microvasculature years after the acute 
illness and are at increased long-term cardiovascular risk.
We aimed to investigate whether participants with past 
TSS have quantitative subclinical changes in macro- and retinal 
microvascular parameters indicative of a possible increased in car-
diovascular risk. The retinal and coronary vasculature share many 
similarities and respond to common metabolic risk factors.5 We 
hypothesized that, compared with control participants, TSS par-
ticipants have a more adverse macrovascular profile [eg, increased 
carotid and aortic intima-media thickness (IMT), increased pulse 
wave velocity (PWV) and decreased carotid artery distensibility 
and compliance] and retinal microvascular profile (eg, wider ven-
ules, narrower arterioles, reduced fractal dimension and increased 
tortuosity).
PATIENTS AND METHODS
We performed a case-control study including participants 
aged 6–30 years who had TSS at least 2 years previously and con-
trol participants of similar age and sex, recruited from The Royal 
Children’s Hospital Melbourne and Monash Medical Centre, Mel-
bourne, Australia. Cases fulfilled the Centers for Disease Control 
and Prevention case definition for either probable or definite TSS.6 
Exclusion criteria were pregnancy, diabetes, known atherosclerotic 
cardiovascular disease, treatment for hypertension and/or hyper-
lipidemia and chronic auto-immune inflammatory conditions. The 
study was approved by the human research ethics committee of 
both hospitals, and written informed consent was obtained from the 
parents or adult participants.
All data were collected at a single visit after a minimum of 6 hours 
of fasting. Demographic data and anthropometric measurements (BC 
418, Tanita, Tokyo, Japan) were obtained. Pubertal status was based on 
self-reported Tanner stage. The mean of 3 blood pressure measurements 
(SphygmoCor XCEL, AtCor Medical, NSW, Australia) was recorded. 
Blood was collected for measurement of high-sensitivity C-reactive pro-
tein (Abbott Architect, IL), glucose, triglycerides, total cholesterol, high 
density lipoprotein and low density lipoprotein cholesterol (Vitros 5600, 
Ortho-Clinical Diagnostics, NJ) during the study visit.
Carotid and Aortic Intima-Media Thickness
Ultrasound images of the carotid artery and the abdominal 
aorta were acquired using Vivid i (General Electronics Healthcare, 
Little Chalfont, UK) with simultaneous electrocardiogram (ECG) 
gating as previously described.7,8 Cine loops of at least 5 cardiac 
cycles focused on the intima-media complex of the posterior wall 
of the right common carotid artery 1 cm proximal to the carotid 
bulb were recorded for offline analysis. Imaging was focused on the 
distal 10–15 mm of the abdominal aorta.
The IMT of the far wall 1 cm from the carotid bulb was 
measured at end diastole using a semiautomated software, Carotid 
Analyzer for Research (Medical imaging applications LLC, Cor-
alville, IA). The “mean IMT” refers to the average IMT in the 
selected area of measurement while the “maximum IMT” to the 
thickest IMT measurement within that segment.8 The mean of these 
“mean IMT” or “maximum IMT” measurements from 5 end-dias-
tolic frames was used in analyses.8
The 5 best-quality frames of the abdominal aorta were 
selected from the recorded cine loops for analysis using the same 
procedure. All IMT measurements were performed by a sin-
gle grader blinded to subject status. The intrarater reliability was 
assessed on 10 masked subjects. Intraclass correlation for carotid 
IMT and aortic IMT was 0.92 [95% confidence interval (CI): 0.69–
0.98] and 0.89 (95% CI: 0.59–0.97), respectively.
